Clinical predictors of 3-month isoniazid rifapentine (3HP)-related adverse drug reactions (ADR) during tuberculosis preventive therapy (PAnDoRA-3HP study): an observational study protocol

Clinical predictors of 3-month isoniazid rifapentine (3HP)-related adverse drug reactions (ADR) during tuberculosis preventive therapy (PAnDoRA-3HP study): an observational study protocol

Introduction Tuberculosis (TB) is the leading infectious cause of death globally. Despite WHO recommendations for TB preventive therapy (TPT), challenges persist, including incompletion of treatment and adverse drug reactions (ADRs). There is limited data on the 3-month isoniazid and rifapentine (3H...

Full description

Saved in:
Bibliographic Details
Main Authors: Turyahabwe Stavia, Barbara Castelnuovo, Christine Sekaggya-Wiltshire, Kelly E Dooley, Grace Banturaki, Irene Mbabazi, Ruth Mirembe Nabisere, Lucy Alinaitwe, Brian Otaalo, Florence Aber, Juliet Nampala, Rogers Owori, Josephine Bayigga, Jonathan Mayito, Eva Agnes Odongpiny Laker, Moorine Penninah Sekadde, Jotam Pasipanodya, Stella Zawedde‐Muyanja
Format: Article
Language:English
Published: BMJ Publishing Group 2024-12-01
Series:BMJ Open
Online Access:https://bmjopen.bmj.com/content/14/12/e088389.full
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://bmjopen.bmj.com/content/14/12/e088389.full

Similar Items